Under the agreement, the company will investigate the therapeutic effects of ApoGraft-treated stem cells to reduce pulmonary manifestations of COVID-19. ApoGraft has been used in clinical trials with graft versus host disease and mesenchymal stem cells; its anti-graft versus host disease effects may be able to address cytokine storms seen in COVID-19 patients as well as other medical conditions like CAR-T cell adverse effects, according to the firm.

The agreement allows for the firm to leverage its ApoGraft clinical data and regulatory approvals to expedite the cytokine storm therapy for COVID-19 as well as CAR-T related cytokine storm conditions. The firm has completed the technology and material transfer and is currently conducting preclinical studies related to COVID-19.

Nasal, oral antiseptics show antiviral activity against SARS-CoV-2
Veloce BioPharma has reported that its nasal and oral antiseptics are effective against SARS-CoV-2, the virus responsible for COVID-19.

Are interferons a viable therapeutic intervention for COVID-19?
Significantly improved viral clearance and reductions in inflammatory cytokines are observed in COVID-19 patients treated with interferons, according...

Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...

Proteomics provides insights into SARS-CoV-2 infection, potential therapies
Scientists tested a series of compounds for blocking the replication of SARS-CoV-2 using a novel proteomics approach. The method, which helped identify...

Exyte, Univercells fast track construction for COVID-19 vaccines
High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible...